Pharmaids Pharmaceuticals share news and announcements
BSE: 524572Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹28.29.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹102 Cr2,774th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 1 Jun 2026
- 2.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- −8.5%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹6.70 crore of one-off items, the largest of them in the quarter to Jun 2026.
- −21.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- −15.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 1 Jun 2026
- 0.44
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,482
Pharmaids Pharmaceuticals share news and announcements
617 announcements, routine notices left out, newest first. Page 10 of 13.
Apr 2019
Feb 2019
12 Feb · Outcome Of 3Rd Quarter Ended 31-12-2018 Financial Resulsts
4 Feb · Board meeting
Meeting on 12 Feb 2019: quarterly results
Jan 2019
14 Jan · Shareholding for the Period Ended December 31, 2018
Shareholding Pattern for the Period Ended December 31, 2018. For more details, kindly Click ....7 Jan · Statement Of Investor Complaints For The Quarter Ended December 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Nov 2018
19 Nov · Statement Of Investor Complaints For The Quarter Ended September 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 013 Nov · Management
1 Nov · Certificate Under Reg Reg40(9) Of SEBI
Oct 2018
17 Oct · Shareholding for the Period Ended September 30, 2018
Shareholding Pattern for the Period Ended September 30, 2018. For more details, kindly Click ....
Sep 2018
Aug 2018
13 Aug · Management
Jul 2018
18 Jul · Shareholding for the Period Ended June 30, 2018
Shareholding Pattern for the Period Ended June 30, 2018. For more details, kindly Click ....18 Jul · Board meeting
18 Jul · Board meeting
10 Jul · Board Meeting To Approve The Agenda
7 Jul · Statement Of Investor Complaints For The Quarter Ended June 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
May 2018
12 May · Limited Review Report For March,2018
12 May · Board meeting
7 May · Board meeting
6 May · Results
Apr 2018
27 Apr · 4TH QTR BOARD MEETING
23 Apr · Board Meeting For The Quarter Ended 31-3-2018
23 Apr · Board meeting
12 Apr · Regulation 40(9) For The Year Ended 31-3-2018
12 Apr · Regulation 7(3) For The Year Ended 31-3-2018
10 Apr · Shareholding for the Period Ended March 31, 2018
Shareholding Pattern for the Period Ended March 31, 2018. For more details, kindly Click ....7 Apr · Statement Of Investor Complaints For The Quarter Ended March 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Feb 2018
15 Feb · Management
3 Feb · Board meeting
Jan 2018
13 Jan · Shareholding for the Period Ended December 31, 2017
Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click ....10 Jan · Statement Of Investors Complaints Under Regulation 13(3) Of The SEBI For The Quarter Ended 31-12-2017
Dec 2017
Nov 2017
18 Nov · Submission Of Regulation 40(9) Of SEBI (Listing Obligation And Disclosure Requirments) Reg. 2015
15 Nov · Submission Of 2Nd Quarter Half Year Ended 30-9-2017 Limited Review Report
3 Nov · Board meeting
Oct 2017
11 Oct · Shareholding for the Period Ended September 30, 2017
Shareholding Pattern for the Period Ended September 30, 2017. For more details, kindly Click ....
Sep 2017
29 Sep · Meeting